Humana vs Teva Pharmaceutical Industries

Humana (HUM), health care, and Teva Pharmaceutical Industries (TEVA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Humana is worth $53.4B on the stock market and Teva Pharmaceutical Industries $49.4B: Humana is valued at 8% more. Humana trades at 43.4 times earnings and Teva Pharmaceutical Industries at 98.4; operating margins in their latest fiscal years were 2.09% and 12.5%. Over the past year Humana's share price has moved +97.0% and Teva Pharmaceutical Industries's +71.4%.

Key facts

Humana market value
$53.4B
Teva Pharmaceutical Industries market value
$49.4B
Humana P/E
43.4
Teva Pharmaceutical Industries P/E
98.4
Humana revenue
$129.7BFY to 2025-12-31
Teva Pharmaceutical Industries revenue
$17.3BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Humana vs Teva Pharmaceutical Industries: every measure side by side
Measure Humana Teva Pharmaceutical Industries
SectorHealth CareHealth Care
Country United States Israel
Fiscal year ends2025-12-312025-12-31
Size
Market cap$53.4Bhigher$49.4Blower
Revenue$129.7Bhigher$17.3Blower
Earnings$1.2Blower$1.4Bhigher
Employees67,060higher31,173lower
Total assets$48.9Bhigher$40.7Blower
Valuation
P/E43.4lower98.4higher
P/S0.4lower2.9higher
P/B2.8—
Dividend yield0.77%—
Profitability
Operating margin2.09%lower12.5%higher
Balance sheet
Net assets$17.7Bhigher$7.9Blower
Total liabilities$31.2Blower$32.8Bhigher
Total debt$12.4B—
Cash on hand$4.2Bhigher$3.6Blower
Price change
Today-3.57%lower-0.59%higher
1 year+97.0%higher+71.4%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Humana / Teva Pharmaceutical Industries). Who owns HUM · Who owns TEVA

Further comparisons

Learn

Questions and answers

Which is bigger, Humana or Teva Pharmaceutical Industries?

By market value, Humana is the larger: $53.4B against $49.4B for Teva Pharmaceutical Industries. By revenue in its latest fiscal year, Humana is the larger: $129.7B against $17.3B for Teva Pharmaceutical Industries.

Which has the higher P/E ratio?

Teva Pharmaceutical Industries: 98.4, against 43.4 for Humana. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Teva Pharmaceutical Industries: 12.5%, against 2.09% for Humana. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Humana and Teva Pharmaceutical Industries?

In their latest 13F filings, Larry Robbins holds both.

Cite this page

Funkfolio, “Humana vs Teva Pharmaceutical Industries”, data as of 17 November 2026. https://funkfolio.com/compare/hum-vs-teva

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.